title: The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus.
abstract: The aim of this study was to evaluate the role of radiotherapy in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVT) and to determine the prognostic factors for overall survival. Altogether, 106 patients with HCC and PVT referred for radiotherapy between 2004 and 2009 were retrospectively reviewed. A total of 60 Gy in 30 daily fractions was delivered with intensity-modulated radiotherapy techniques. Patient-related and treatment-related factors were analyzed to evaluate their prognostic significance for the overall survival rate. Complete response was noted in 10 patients and partial response in 55 patients. The liver lesions had become resectable after the completion of radiotherapy in 12 patients, and surgery was subsequently performed. One or two courses of transarterial chemoembolization (TACE) were administered to 19 patients following radiotherapy. The 1-year and 2-year overall survival rates were 34.7% and 11%, respectively, and the median survival was 7 months for the entire cohort of patients. Post-radiotherapy treatment modality, response to radiotherapy and JIS score were demonstrated as independent prognostic factors for overall survival (P = 0.003, P < 0.001, P < 0.001, respectively). For patients who received surgical intervention after radiotherapy, the median survival was 30 months and the 2-year overall survival rate was 67%. Radiotherapy achieved a 61.5% objective response rate and prolonged survival in patients with PVT. The liver tumors had become resectable after radiotherapy in 11% of patients. Our results suggested that radiotherapy could offer survival benefits and should be considered as a treatment option for patients with PVT. Radiotherapy could also be considered as a preoperative treatment modality in patients with HCC and PVT.
authors.affiliation: Department of Radiation Oncology, E-DA Hospital, Kaohsiung City, Taiwan Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung City, Taiwan sayeh@outlook.com.
authors.forename: Shyh-An
authors.initials: SA
authors.lastname: Yeh
authors.affiliation: Department of General Surgery, E-DA Hospital, Kaohsiung City, Taiwan.
authors.forename: Yaw-Sen
authors.initials: YS
authors.lastname: Chen
authors.affiliation: Department of Gastroenterology, E-DA Hospital, Kaohsiung City, Taiwan.
authors.forename: Daw-Shyong
authors.initials: DS
authors.lastname: Perng
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000532:radiotherapy*; D015984:Causality; D015897:Comorbidity; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein / Q000528:radiation effects; D015995:Prevalence; D020266:Radiotherapy, Conformal / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013624:Taiwan / Q000453:epidemiology; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000401:mortality* / Q000517:prevention & control*
keywords: hepatocellular carcinoma; portal vein; preoperative; radiotherapy